Thyroid incidentalomas in patients with multiple endocrine neoplasia type 1

Lutske Lodewijk, Pim J Bongers, Jakob W Kist, Elfi B Conemans, Joanne M de Laat, Carla R C Pieterman, Anouk N A van der Horst-Schrivers, Ciska Jorna, Ad R Hermus, Olaf M Dekkers, Wouter W de Herder, Madeleine L Drent, Peter H Bisschop, Bas Havekes, Inne H M Borel Rinkes, Menno R Vriens and Gerlof D Valk

Department of Oncology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands, Departments of Endocrinology and Surgery, University Medical Center Groningen, 9700 RB Groningen, The Netherlands, Department of Endocrinology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands, Departments of Endocrinology and Metabolism and Clinical Epidemiology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands, Department of Internal Medicine, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands, Department of Internal Medicine, VU University Medical Center, 1007 MB Amsterdam, The Netherlands, Departments of Endocrinology and Metabolism, Academic Medical Center, 1100 DD Amsterdam, The Netherlands and Department of Internal Medicine, Division of Endocrinology, Maastricht University Medical Center, 6202 AZ Maastricht, The Netherlands

Correspondence should be addressed to G D Valk
Email G.D.Valk@umcutrecht.nl

Abstract

Objective: Currently, little is known about the prevalence of thyroid tumors in multiple endocrine neoplasia type 1 (MEN1) patients and it is unclear whether tumorigenesis of these thyroid tumors is MEN1-related. The aim of the study was to assess the prevalence of thyroid incidentalomas in MEN1 patients compared with non-MEN1 patients and to verify whether thyroid tumorigenesis is MEN1-related.

Design: A cross-sectional study.

Methods: The study included two groups: patients with MEN1 and a matched non-MEN1 control group without known thyroid disease, who underwent an ultrasound of the neck for the localization of parathyroid adenoma. Ninety-five MEN1 patients underwent ultrasound of the neck and were matched on gender and age with non-MEN1 patients. The prevalence of thyroid incidentalomas described in the ultrasound report was scored. Multinodular goiters, solitary nodes, and cysts were scored as incidentalomas. Presence of nuclear menin expression was evaluated by menin immunostaining of the thyroid tumors.

Results: In the MEN1 group, 43 (45%) patients had a thyroid incidentaloma compared with 48 (51%) in the non-MEN1 group, of which 14 (15%) and 16 (17%), respectively, were solitary nodes. Menin was expressed in the nuclei of all evaluated thyroid tumors.

Conclusions: MEN1 patients do not have a higher prevalence of thyroid incidentalomas compared with primary hyperparathyroidism patients without the diagnosis of MEN1. Menin was expressed in the thyroid tumors of MEN1 patients.

Introduction

Multiple endocrine neoplasia type 1 (MEN1) syndrome is characterized by the combined occurrence of pituitary tumors, primary hyperparathyroidism (pHPT), pancreatic and duodenal neuroendocrine tumors (NET), adrenal adenomas, and NETs of stomach, lung, and thymus (1). Recently, MEN1 has also turned out to be a breast cancer
susceptible syndrome (2). The syndrome is caused by an inactivating germline mutation in the MEN1 gene, which encodes for the tumor suppressor protein menin. Tumorigenesis of MEN1-related tumors is characterized by loss of menin expression or the production of nonfunctional menin in case of missense (or in-frame) alterations of the MEN1 gene (3). At present, little is known about the prevalence of thyroid tumors in MEN1 patients. Marx et al. found a prevalence of 12% thyroid tumors (8% follicular adenoma and 5% papillary thyroid carcinoma) in 130 MEN1 patients. These patients were screened for all types of endocrine abnormalities (4). The recently published MEN1 guideline reports that thyroid tumors (adenomas, colloid goiters, and carcinomas) occur in more than 25% of patients with MEN1. Subsequently, the guideline states that ‘because of the high prevalence of thyroid abnormalities in the general population, the association of thyroid abnormalities with MEN1 may be incidental and not significant’ (1). However, the lack of evidence regarding the clinical relevance of thyroid tumors might cause an extra dilemma for both endocrinologist and endocrine surgeon treating patients with MEN1.

Primary hyperparathyroidism (pHPT) occurs in 90% of the MEN1 patients. Therefore, a substantial part of this population undergoes a neck ultrasound to localize parathyroid adenomas (5). Because of the anatomical relationship between thyroid and parathyroid glands, it is inevitable that the thyroid is imaged during the neck ultrasound, which increases the chance of incidentally finding a thyroid tumor.

The aim of this study was to assess the prevalence of thyroid incidentalomas in the Dutch MEN1 population compared with a matched reference group of non-MEN1 patients. To support the epidemiologic findings, we studied menin expression in thyroid tumors of MEN1 patients by immunohistochemistry to assess whether loss of nuclear menin was present.

Subjects and methods

Study group

All MEN1 patients in the Dutch MEN1 Study Group (DMSG) database were identified as described previously (325 patients) (6). From this database, data regarding demographics, mutation status (according to the Human Genome Variation Society nomenclature) (7), MEN1 manifestations, imaging, surgery, and histology reports were extracted. For further analysis, patients were selected who had a neck ultrasound because of pHPT in which the thyroid was described (102 patients; Fig. 1). The baseline characteristics of 102 patients were compared with the other MEN1 patients to verify whether it was a representative subgroup (Table 1).

As a non-MEN1 reference group, 201 consecutive patients who underwent neck ultrasound between 2003 and 2012 for pHPT, not having MEN1 or known thyroid disease, were identified from the hospital radiology database of the University Medical Centers of Utrecht and Groningen in The Netherlands. This reference group will further be referred to as the non-MEN1 group. As age and gender differed significantly in the MEN1 and the non-MEN1 groups, patients were matched (1:1) on these variables via the ‘case–control matching’ extension in SPSS. For age, a spread of 3 years was accepted for the matching. In total, 95 patients could be matched. Seven MEN1 patients had to be excluded because no match was available. These consisted of five females and two men with a median age of 21 years, ranging from 15 to 33 years. Of those seven patients, two patients had a cyst.

Multinodular goiters, solitary nodes, and cysts that were identified by the ultrasounds of the neck were scored. By definition these tumors are incidentalomas.

Immunohistochemistry

As a proxy, for menin expression, immunohistochemistry was performed on formalin-fixed paraffin-embedded (FFPE) tissues from five thyroid samples and a negative control sample. However, certain types of the MEN1 mutations do not lead to an altered expression of menin, but due to these mutations there is a nonfunctional protein. Therefore, we listed the mutations per sample in Supplementary Table 1, see section on supplementary data.
given at the end of this article. All thyroid tumors were selected and evaluated by a dedicated pathologist (PJvD). As a negative control, we used a sample in which, by sequencing of the DNA, loss of heterozygosity (LOH) was proven. This sample was from a patient with infiltrative ductal carcinoma of the breast with a germline nonsense mutation (c.377G>A(p.Trp126X)) (2). All tissues were sampled from surgical specimen according to the standard procedure in the University Medical Center Utrecht. The slides were deparaffinized with xylene and rehydrated in decreasing ethanol dilutions. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide. Antigen retrieval was achieved by boiling slides in citrate buffer (pH 6.0) for 20 min. The slides were then incubated with the rabbit polyclonal antibody against menin (Menin, A300-105A, Bethyl Laboratories, Inc., Montgomery, TX, USA), diluted at 1:1600 for 1 h at room temperature. For detection of primary antibodies, goat anti-mouse poly-HRP (Powervision, Immunologic, Immunovision Technologies, Brisbane, CA, USA) was used. All slides were developed with diaminobenzidine (DAB). The slides were counterstained with filtered hematoxylin, dehydrated through a graded series of ethanol, immersed in xylene, and mounted. Menin staining was reviewed by an experienced pathologist and compared with the negative control.

### Statistical analyses

Continuous variables are expressed as means with a S.D. if normally distributed and as median (25 and 75% percentile) if not. Categorical and dichotomous variables are expressed as absolute numbers (%). Matching was performed by the case–control matching function available in SPSS. Student’s t-test, Mann–Whitney U test, and Pearson’s χ² test were used where appropriate. Statistical significance was reached when P value was smaller than 0.05. Calculations were performed using SPSS/PC version 23.0.

### Results

#### Baseline comparison

The presence of thyroid was mentioned in the report of the neck ultrasound in 102 patients (32%) of a total of 323 MEN1 patients. In 31 (10%) patients, an ultrasound was performed but the presence of thyroid was not mentioned in the report. No ultrasound was performed between 1990 and 2010 in 190 (59%) MEN1 patients (Fig. 1). Patient characteristics of the groups with and without a neck ultrasound were compared with baseline characteristics

### Table 1  Baseline comparison between MEN1 patients with or without neck ultrasound.

<table>
<thead>
<tr>
<th></th>
<th>Comparison group (n=221)</th>
<th>Analysis group (n=102)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n (%)</td>
<td>120 (54.3)</td>
<td>68 (66.7)</td>
<td>0.04</td>
</tr>
<tr>
<td>Age, mean in years (s.d.)</td>
<td>46.7 (16.5)</td>
<td>51.9 (14.8)</td>
<td>0.01</td>
</tr>
<tr>
<td>Follow-up, mean in years (s.d.)</td>
<td>10.2 (9.9)</td>
<td>10.5 (8.5)</td>
<td>0.82</td>
</tr>
<tr>
<td>pHPT, n (%)</td>
<td>161 (73.6)</td>
<td>102 (100.0)</td>
<td>0.00</td>
</tr>
<tr>
<td>Type of mutation, n (%)</td>
<td></td>
<td></td>
<td>0.29</td>
</tr>
<tr>
<td>Clinical diagnoses*</td>
<td>15 (6.8)</td>
<td>15 (14.7)</td>
<td></td>
</tr>
<tr>
<td>Nonsense</td>
<td>30 (13.6)</td>
<td>18 (17.6)</td>
<td></td>
</tr>
<tr>
<td>Missense</td>
<td>43 (19.5)</td>
<td>18 (17.6)</td>
<td></td>
</tr>
<tr>
<td>Frameshift</td>
<td>68 (30.8)</td>
<td>32 (31.4)</td>
<td></td>
</tr>
<tr>
<td>Splice</td>
<td>12 (5.4)</td>
<td>2 (2.0)</td>
<td></td>
</tr>
<tr>
<td>Unclassified</td>
<td>2 (0.9)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Large deletionsb</td>
<td>48 (21.7)</td>
<td>15 (14.7)</td>
<td></td>
</tr>
<tr>
<td>Unknownc</td>
<td>3 (1.4)</td>
<td>2 (2.0)</td>
<td></td>
</tr>
</tbody>
</table>

**pHPT**, primary hyperparathyroidism.

*Clinical diagnoses are patients with two or more of the major manifestations of MEN1 without a germline mutation.

bLarge deletions include in-frame deletions, deletions of exon 1 and 2, deletions of exon 1, 2, and 3, and deletions of the entire MEN1 gene.

cUnknown consists of patients with clinical diagnosis of MEN1 in whom either no genetic testing is performed or the exact location of the mutation is unknown.

### Table 2  Thyroid incidentalomas in MEN1 patients compared with a matched control group.

<table>
<thead>
<tr>
<th></th>
<th>MEN1 (n=95)</th>
<th>Non-MEN1 (n=95)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n (%)</td>
<td>63 (66)</td>
<td>63 (66)</td>
<td>–</td>
</tr>
<tr>
<td>Age at date of ultrasound, mean (s.d.)</td>
<td>48.3 (14.3)</td>
<td>46.6 (13.8)</td>
<td>–</td>
</tr>
<tr>
<td>Incidentaloma, n (%)</td>
<td>43 (45)</td>
<td>48 (51)</td>
<td>NS</td>
</tr>
<tr>
<td>Multinodular goitre, n (%)</td>
<td>25 (26)</td>
<td>29 (31)</td>
<td>NS</td>
</tr>
<tr>
<td>Solitary node, n (%)</td>
<td>14 (15)</td>
<td>16 (17)</td>
<td>NS</td>
</tr>
<tr>
<td>Cyst, n (%)</td>
<td>4 (4)</td>
<td>4 (4)</td>
<td>NS</td>
</tr>
</tbody>
</table>
The group that underwent ultrasound of the neck consisted of more female patients (68 (66.7%) vs 120 (54.3%)) and was significantly older (51.9 (14.8) vs 46.7 (16.5)). There was no difference in mean follow-up time and the type of mutation between the groups with and without a neck ultrasound.

**Thyroid incidentalomas**

In 43 MEN1 patients (45%) and 48 non-MEN1 patients (51%), incidentalomas of the thyroid were found on neck ultrasound. The tumors consisted of 25 (26%) and 29 (31%) multinodular goiters, 14 (15%) and 16 (17%) solitary nodes, four (4%) and four (4%) cysts in the MEN1 group and the non-MEN1 group, respectively. No significant differences were found (Table 2). When reported, size of the solitary nodes was also analyzed. The median size of the solitary nodes was 6 mm (Interquartile range (IQR) 4.5–11 mm) in the MEN1 group and 8 mm (IQR 4.0–9.0 mm) in the non-MEN1 group (P value 0.94).

**Thyroid histology**

From 17 MEN1 patients, the histology reports of the thyroid tumors were available and the diagnoses are given in Table 3. Follicular adenomas and nodular dysplasia were most prevalent. Immunohistochemistry was performed in a representative subset of the different types of thyroid tumors. In all thyroid tumors, we tested whether menin was present by immunohistochemical staining of the nucleus of adjacent normal and tumor tissues. In the control sample, no menin expression was found, indicating loss of heterozygosity (Fig. 2 and Supplementary Figure 1, see section on supplementary data given at the end of this article).

**Discussion**

The results of this study show that the prevalence of thyroid incidentalomas in patients with MEN1 is equal to a matched reference group with non-MEN1 patients. These results are in-line with the suggestion in the

### Table 3 Diagnoses of the thyroid tumors after histologic examination in MEN1 patients.

<table>
<thead>
<tr>
<th>Histologic examinations</th>
<th>n = 17</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multifocal micro-invasive medullary thyroid carcinoma</td>
<td>1</td>
</tr>
<tr>
<td>Micro-invasive follicular thyroid carcinoma</td>
<td>1</td>
</tr>
<tr>
<td>Follicular adenoma</td>
<td>4</td>
</tr>
<tr>
<td>Multinodular goiter</td>
<td>2</td>
</tr>
<tr>
<td>Nodular dysplasia</td>
<td>5</td>
</tr>
<tr>
<td>Nodular hyperplasia</td>
<td>3</td>
</tr>
<tr>
<td>Lymphocytic thyroiditis</td>
<td>1</td>
</tr>
</tbody>
</table>

![Figure 2](https://www.eje-online.org) Immunohistochemical analysis of menin protein expression in the nuclei of five thyroid tumors from MEN1 patients and absence of expression in one infiltrating ductal carcinoma of the breast from a MEN1 patient with proven LOH. Pictures are taken with a 20× magnification, inlays with 40× magnification. (A) Infiltrative ductal carcinoma of the breast; (B) hyperplastic node; (C) microinvasive medullary thyroid carcinoma; (D) multinodular goiter; (E) follicular adenoma; and (F) microinvasive follicular thyroid carcinoma.
recently updated guideline, that the high percentage (25%) of thyroid tumors occurring in MEN1 patients is incidental and not significant (1). These epidemiologic results are strongly supported by the immunohistochecmistry, which show a positive menin staining indicating the presence of intact nuclear menin expression in a representative subset of thyroid tumors found in patients with MEN1.

The non-MEN1 patients were considered the best available control group facing the fact that a neck ultrasound was performed for the same indication as in the MEN1 patients. As MEN1 patients present with pHPT at a young age, not all MEN1 patients could be matched. Also in this young patient group, a very low prevalence of thyroid incidentalomas was found which is in-line with what one can expect in the general population.

In literature, prevalence rates for solitary nodes in healthy individuals are around 10% compared with 15% in our study (8, 9, 10, 11). Owing to the retrospective character of the study, all patients (n = 31) who underwent a neck ultrasound in which the thyroid was not mentioned in the report were excluded. If we assume that there was no solitary node in those 31 neck ultrasounds, our prevalence would be similar (11%) to the prevalence rates reported in literature.

From 17 MEN1 patients, histology reports were available from thyroid tumors found by ultrasound. Of those 17 patients, one patient had a microinvasive medullary thyroid carcinoma and one patient had a microinvasive follicular thyroid carcinoma, and the other 15 showed benign pathology. MEN1-related tumors are characterized by loss of the second allele of MEN1 gene, encoding for the protein menin, resulting in no functional copies of the gene (12). In four case series of MEN1 patients with thyroid carcinoma, loss of heterozygosity (LOH) was examined. The results did not show any LOH which indicates no etiological relation between the presence of MEN1 mutation and thyroid carcinoma (13, 14, 15, 16). We assessed loss of menin expression by immunohistochemistry in a representative subset of diagnoses; in all evaluated tissue menin was expressed throughout the tumor and adjacent normal thyroid tissue. This indicates that there is no haploinsufficiency, i.e. the intact copy of the MEN1 gene produces enough protein to bring about a WT condition.

It is a clinical challenge for both endocrinologists and surgeons to deal with thyroid incidentalomas in MEN1 patients. On the one hand, the burden of the patient needs to be as low as possible, and on the other hand, malignancies need to be identified and treated as early as possible. Our results indicate that in case of a thyroid incidentaloma in MEN1 patients, prevailing guidelines for thyroid incidentalomas in the general population can be followed.

In conclusion, our results show no difference in the prevalence of thyroid incidentalomas in MEN1 patients compared with patients with pHPT without the diagnosis of MEN1. The epidemiologic findings were validated by menin expression in the nuclei.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/EJE-14-0897.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Acknowledgements
The authors thank Paul J van Diest for scoring of the menin staining.

References


---

Received 20 October 2014
Revised version received 18 December 2014
Accepted 7 January 2015